



Corrigendum

Corrigendum to “ESTRO/EANO recommendation on reirradiation of glioblastoma” [Radiother. Oncol. 204 (2025) 110696]

Nicolaus Andratschke^{a,*}, Astrid Heusel^a, Nathalie L. Albert^b, Filippo Alongi^{c,d}, Brigitta G. Baumert^e, Claus Belka^f, Antonella Castellano^g, Frederic Dhermain^h, Sara C. Erridgeⁱ, Anca-L. Grosu^j, Franciscus Lagerwaard^k, Slavka Lukacova^l, Per Munck af Rosenschold^m, Maximilian Niyaziⁿ, Carsten Nieder^{o,p}, Matthias Preusser^q, Marion Smits^r, Damien C. Weber^{a,s}, Wolfgang A Weber^t, Michael Weller^u, Aoife Williamson^v, Giuseppe Minniti^{w,x}

^a Department of Radiation Oncology, University Hospital Zürich, Switzerland

^b Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany

^c Advanced Radiation Oncology Department, IRCCS Sacro Cuore don Calabria Hospital, Negrar di Valpolicella, Italy

^d University of Brescia, Italy

^e Institute of Radiation-Oncology, Cantonal Hospital Graubünden, Chur, Switzerland

^f Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany

^g Neuroradiology Unit and CERMAC, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy

^h Radiotherapy Department, Gustave Roussy University Hospital, Villejuif Cedex, France

ⁱ Edinburgh Centre for Neuro-Oncology, Western General Hospital, University of Edinburgh, Edinburgh, UK

^j Department of Radiation Oncology, University Medical Center Freiburg, Germany

^k Department of Radiation Oncology, VU University Medical Center, Amsterdam, the Netherlands

^l Department of Oncology, Aarhus University Hospital, Aarhus, Denmark

^m Radiation Physics, Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, and Medical Radiation Physics, Lund University, Lund, Sweden

ⁿ Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany

^o Department of Oncology and Palliative Medicine, Nordland Hospital Trust, Bodø, Norway

^p Department of Clinical Medicine, Faculty of Health Sciences, UiT the Arctic University of Norway, Tromsø, Norway

^q Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria

^r Department of Radiology and Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands

^s Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland

^t Department of Nuclear Medicine, Technical University Munich, Germany

^u Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland

^v Department of Radiotherapy, Beatson West of Scotland Cancer Centre, Glasgow, UK

^w Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy

^x IRCCS Neuromed, Pozzilli, IS, Italy

The authors were made aware that the wrong a/b was used for EQD2 calculation. This may lead to erroneous dose calculation and dose sum assessment.

The error on page 4 of the article PDF reads: “use of a regime delivering a biologically equivalent dose above 36 Gy in 18 fractions to

the target (corresponding to a EQD2Gy of 36 Gy; Table 4; recommendation 8; using an a/b value of 3 Gy).”

Correctly, it should read: “using an a/b value of 10 Gy).”

The error has been corrected in the online version.

DOI of original article: <https://doi.org/10.1016/j.radonc.2024.110696>.

* Corresponding author.

E-mail address: nicolaus.andratschke@usz.ch (N. Andratschke).

<https://doi.org/10.1016/j.radonc.2026.111438>

Available online 18 February 2026

0167-8140/© 2026 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).